These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26289076)

  • 21. Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial.
    Busard CI; Menting SP; van Bezooijen JS; van den Reek JM; Hutten BA; Prens EP; de Jong EM; van Doorn MB; Spuls PI
    Trials; 2017 Feb; 18(1):52. PubMed ID: 28148280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adalimumab for maintenance of remission in Crohn's disease.
    Townsend CM; Nguyen TM; Cepek J; Abbass M; Parker CE; MacDonald JK; Khanna R; Jairath V; Feagan BG
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012877. PubMed ID: 32413933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial.
    van der Heijde D; Sieper J; Maksymowych WP; Lambert RG; Chen S; Hojnik M; Anderson JK; Pangan AL
    Arthritis Res Ther; 2018 Mar; 20(1):61. PubMed ID: 29587851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    Verhoef LM; van den Bemt BJ; van der Maas A; Vriezekolk JE; Hulscher ME; van den Hoogen FH; Jacobs WC; van Herwaarden N; den Broeder AA
    Cochrane Database Syst Rev; 2019 May; 5(5):CD010455. PubMed ID: 31125448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-TNFs in axial spondyloarthritis.
    Kocijan R; Muschitz C; Rech J
    Wien Med Wochenschr; 2015 Jan; 165(1-2):10-3. PubMed ID: 25572548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing a tapering strategy to the standard dosing regimen of TNF inhibitors in rheumatoid arthritis patients with low disease activity.
    Plasencia C; Wolbink G; Krieckaert CL; Kneepkens EL; Turk S; Jurado T; Martínez-Feito A; Navarro-Compán V; Bonilla G; Villalba A; Peiteado D; Nuño L; Martín-Mola E; Nurmohamed MT; van der Kleij D; Rispens T; Pascual-Salcedo D; Balsa A
    Clin Exp Rheumatol; 2016; 34(4):655-62. PubMed ID: 27214767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Remission and possible discontinuation of biological therapy in axial spondyloarthritis.
    Braun J; Sieper J
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S33-6. PubMed ID: 24129134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-TNF-alpha therapy with infliximab in spondyloarthritides.
    Baraliakos X; Braun J
    Expert Rev Clin Immunol; 2010 Jan; 6(1):9-19. PubMed ID: 20383886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Presence of subclinical inflammation in axial spondyloarthritis patients with NSAID/anti-TNF-α drug-induced clinical remission.
    Zong HX; Xu SQ; Wang JX; Chu YR; Chen KM; Wang C; Tong WQ; Wang XL
    Clin Rheumatol; 2022 May; 41(5):1403-1412. PubMed ID: 35083561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disease-modifying Antirheumatic Drugs (DMARD) and Combination Therapy of Conventional DMARD in Patients with Spondyloarthritis and Psoriatic Arthritis with Axial Involvement.
    Simone D; Nowik M; Gremese E; Ferraccioli GF
    J Rheumatol Suppl; 2015 Nov; 93():65-9. PubMed ID: 26523061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis (BACK-OFF JSpA): study protocol for a randomized pragmatic trial.
    Weiss PF; Sears CE; Brandon TG; Forrest CB; Neu E; Kohlheim M; Leal J; Xiao R; Lovell D
    Trials; 2023 Feb; 24(1):100. PubMed ID: 36755328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is reduction or discontinuation of therapy an acceptable possibility in psoriatic arthritis?
    Mease P
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S59-62. PubMed ID: 24129140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study.
    Glinatsi D; Heiberg MS; Rudin A; Nordström D; Haavardsholm EA; Gudbjornsson B; Østergaard M; Uhlig T; Grondal G; Hørslev-Petersen K; van Vollenhoven R; Hetland ML
    Trials; 2017 Apr; 18(1):161. PubMed ID: 28376912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2.
    Sieper J; Lenaerts J; Wollenhaupt J; Rudwaleit M; Mazurov VI; Myasoutova L; Park S; Song Y; Yao R; Chitkara D; Vastesaeger N;
    Ann Rheum Dis; 2014 Jan; 73(1):108-13. PubMed ID: 23740231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort.
    Ciurea A; Scherer A; Exer P; Bernhard J; Dudler J; Beyeler B; Kissling R; Stekhoven D; Rufibach K; Tamborrini G; Weiss B; Müller R; Nissen MJ; Michel BA; van der Heijde D; Dougados M; Boonen A; Weber U;
    Arthritis Rheum; 2013 Dec; 65(12):3096-106. PubMed ID: 23983141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis: A retrospective study.
    Alegre-Sancho JJ; Juanola X; Rodríguez-Heredia JM; Manero J; Villa-Blanco I; Laiz A; Arteaga MJ; Cea-Calvo L; González CM
    Medicine (Baltimore); 2021 Apr; 100(13):e25223. PubMed ID: 33787605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How important is early therapy in axial spondyloarthritis?
    Sieper J; Braun J
    Rheum Dis Clin North Am; 2012 Aug; 38(3):635-42. PubMed ID: 23083760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.